Mivelsiran, an RNA therapeutic being developed for early-stage Alzheimer's disease, has shown encouraging early-stage data. According to Sharon Cohen, MD, FRCPC, medical director of the Toronto Memory Program at the University of Toronto, an ongoing phase 1 study is assessing the drug's potential in this patient population.
BHV-7000 for Focal Epilepsy
Biohaven has commenced a phase 2/3 clinical trial to investigate BHV-7000, a potassium inhibitor, for the treatment of focal epilepsy. Aliza Alter, MD, a pediatric neurologist at the Institute of Neurology in Livingston, New Jersey, commented on the newly initiated study, highlighting its potential as a novel antiseizure medication.
Mirdametinib for Neurofibromatosis
SpringWorks Therapeutics is prioritizing the development of mirdametinib, a treatment for both adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas. Jim Cassidy, MD, PhD, chief medical officer at SpringWorks Therapeutics, discussed the potential of mirdametinib in advancing neurofibromatosis care.
Ravulizumab and NMOSD Management
Michael Levy, MD, PhD, presented 138-week data on ravulizumab for NMOSD, focusing on long-term relapse rates, and shared practical tips for effective NMOSD management in clinical settings. The data suggests sustained efficacy of ravulizumab in reducing relapse rates over the long term.
